Meta-analysis showed that azithromycin does not appear to reduce the frequency of recurrent cardiac events in patients with CAD. Results from ongoing trials may clarify the role of azithromycin in ...
In our meta-analysis of randomized, controlled trials, administration of azithromycin did not demonstrate a significant reduction in recurrent coronary events when compared with placebo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback